Compare FCUV & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCUV | ENSC |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.7M |
| IPO Year | 2013 | N/A |
| Metric | FCUV | ENSC |
|---|---|---|
| Price | $0.80 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,023.00 | N/A |
| Revenue This Year | N/A | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.23 |
| 52 Week High | $12.83 | $2.75 |
| Indicator | FCUV | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 35.37 |
| Support Level | $0.63 | N/A |
| Resistance Level | $0.85 | $0.44 |
| Average True Range (ATR) | 0.30 | 0.05 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 13.46 | 32.62 |
Focus Universal Inc focuses on commercializing universal smart technology and financial reporting software. It plans to utilize its universal smart technology for smart meters and automation systems, which will be incorporated into IoT devices. The company has developed the five proprietary platform technologies: device on a chip; universal smart instrumentation platform (USIP); 5G ultra-narrowband technology; ultra-narrowband power line communication (PLC) technology; and its financial reporting software. The company consists of two segments: LED and IoT Installation Services, and SEC Financial Software segment. It derives the majority of the revenue from LED and IoT Installation Services segment which handles LED and IoT installation and management business.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.